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Abstract
The log-rank test is a cornerstone of phase III oncology clinical trials. However, there are at least three different mathematical procedures that can be 
named the log-rank test and two of them are widely used by commercial statistical programs. Consequently, different P values can be obtained. In 
the case of a borderline statistical significance, this can mean the difference between the evidence (significant P value) and merely an observation. 
Since all three methods can be reported under the same name, space for possible data manipulation occurs. This should be of a particular concern 
in a drug regulatory context. Randomized clinical trials with borderline significant results should perhaps be required to report P values calculated 
by all three methods, in order to properly evaluate drug efficacy. An interactive MS Excel spreadsheet that uses all three logrank test variants is 
prepared as a supplementary file accompanying this article. Association of high grade of bone marrow fibrosis with poor outcome in patients with 
myelofibrosis is used as an example.
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Survival analysis based on the method by Kaplan 
and Meier is a cornerstone of phase III oncology 
clinical trials (1). The log-rank test is a statistical test 
of choice to compare survival/time to event of in-
terest between two or more groups of patients. 
However, one name (the log-rank test) can be 
used for three related but different mathematical 
procedures. Two of them are widely employed in-
side different commercial statistical programs. 
“Behind the scenes“ mathematics are not the same 
and thus different results can be obtained. In the 
case of a borderline statistical significance, this can 
mean the difference between the evidence (signif-
icant P value) and merely an observation. In other 
words, two persons analysing the same data set 
with two different statistical programs can “un-
knowingly” reach a different conclusion. Since all 
three methods can be reported under the same 
name, space for possible data manipulation oc-
curs. 
The log-rank test variants
Mathematical overview of all three methods is 
shown in Table 1 and the supplementary file. The 
first method that was proposed by Mantel in 1966 
represents an extension of the Mantel-Haenszel 
procedure for comparing 2 x 2 tables (2). Most 
commercial statistical programs provide it under 
the name of the log-rank test (e.g. STATA, Stata-
Corp v. 14 and MedCalc, MedCalc Software v 16). 
The second method that was developed by Peto 
and Peto in 1972 uses alternative computational 
approach to produce the same test statistic but 
different variance (3). It is computationally simpler 
and therefore easier to calculate by hand/table 
calculator. Although developed later, it was origi-
nally named the log-rank test by the authors and 
the name was thereafter generalized for both pro-
cedures. This method is provided by e.g. Statistica 
StatSoft v. 13 under the name of the log-rank test. 
It should be noted that this program also provides 
the first method proposed by Mantel, but under a 
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Table 1. Mathematical overview of three different log-rank test variants.
Key steps in data 
analysis
The Cox-Mantel test The simple χ2 log-rank test The Peto log-rank test 
Step 1 
(Data sorting)*









P values that correspond to calculated χ2 values are found using one degree of freedom χ2 distribution table.
*Step 1 (Sorting data) is same for all three methods. Intervals are necessary if we want to obtain correct calculations when more 
than one death occurs at the same time (tied observations). All concurrent deaths are considered to happen in the same interval. 
Central calculations for all three methods are interval specific (i.e. occur at death times). 
†Step 2 (Preliminary calculations) is necessary for later calculations of χ2 value. The Cox-Mantel test and the simple χ2 test share 
calculation of observed and expected number of deaths. 
‡O, E, R and I represent observed number of deaths, expected number of deaths, number of patients at risk and number of 
intervals, respectively. Oj, Ej and Rj (j=1,..,I) represent aforementioned parameters at the time of the j-ordered interval. 
§T and V represent test statistic and variance for particular test variant, respectively. The Cox-Mantel test and the Peto log-rank 
test produce the same test statistic. Calculations are done in one of the groups only. Variance for both methods is calculated on a 
whole data-set. 
N, ΛI and W represent number of observations, the Nelson-Aalen estimator for a particular interval and a specific Peto log-rank 
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different name (the Cox-Mantel test). The third 
method is based on the simple χ2 (chi squared) 
principle of analysing observed and expected 
number of events. This method is rarely used by 
commercial statistical programs but deserves to 
be mentioned because it is widely accepted as an 
explanation to the logic behind the test (4). We re-
fer to particular methods throughout our manu-
script and supplementary file as the Cox-Mantel 
test, the Peto log-rank test and the simple χ2 log-
rank test, respectively. All three methods produce 
a one degree of freedom χ2 statistic that is used to 
obtain the corresponding P value. These tests 
should not be confused with weighted two-sam-
ple tests for survival data (Gehan generalization of 
the Wilcoxon test, Peto and Peto generalization of 
the Wilcoxon test, the Tarone-Ware test, the Flem-
ing-Harrington test, etc.) (5).
It is hard to recommend which method should be 
favoured over the other. Variance of the Peto log-
rank test is calculated under the assumption of 
equal censoring and other log-rank tests might 
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perform better if censoring does not occur at ran-
dom with respect to group membership (e.g. if 
withdrawals due to side-effects occur mainly in 
one treatment group) (3). However, it is unclear 
how important in practice unequal censoring is. 
On the other hand, it was suggested that the Cox-
Mantel test tends to underestimate true variance 
(and therefore produce unrealistically lower P val-
ue in comparison to the Peto log-rank test) when 
the test statistic is large in absolute value (6). As we 
have observed in multiple data sets, these two 
tests exchange in providing more significant P val-
ue in different clinical situations. It should be not-
ed that if the assumption of proportional hazards 
is violated (e.g. survival curves cross) neither of the 
log-rank test methods should be used. Alternative 
statistical methods were developed for such situa-
tions (7). 
All three log-rank test variants are considered to 
be the log-rank test and are named as such on dif-
ferent occasions. Actually, medical researchers are 
mostly unaware of the method used and currently, 
there is no discrimination between the log-rank 
test variants in most of published medical litera-
ture. Some statistical programs do not clearly re-
port their method of choice either, and sometimes 
it is almost impossible to know how the P value 
was obtained unless data are recalculated in a 
known manner. Therefore, an interactive MS Excel 
spreadsheet that uses all three methods is pre-
pared as a supplementary file accompanying this 
article. Users are encouraged to experiment with 
the provided data set or test their own, and be-
come more acquainted with the problem. Spread-
sheet can analyse up to 200 entries that can be 
copy-pasted inside corresponding columns and 
can serve as a standalone statistical program. It 
should be noted that it is unethical to “fish” for sig-
nificant P value and to report only one most sig-
nificant result. Such “P value hacking” is strongly 
discouraged by the authors. 
Application of three methods to example 
data set
Primary myelofibrosis (PMF) is a Philadelphia chro-
mosome negative chronic myeloproliferative neo-
plasm (Ph- MPN) originating from transformed he-
matopoietic stem cell (8). Secondary myelofibrosis 
(SMF) can develop from PMF biologically related 
Ph- MPNs and it clinically resembles PMF. Typical 
feature of these diseases is scarring of the bone 
marrow (i.e. myelofibrosis) that can be graded ac-
cording to the current European consensus (9). 
In our example, we have evaluated impact of high-
ly advanced (grade 3) bone marrow fibrosis pre-
sent at the time of diagnosis on overall survival in 
a cohort of 67 patients with PMF and SMF. Data 
were acquired in a retrospective manner and rep-
resent single centre experience. One might have 
the feeling that there is a real effect in place by ob-
serving the Kaplan-Meier curves (Figure 1). But is 
there statistical evidence to support it? Stated in 
other words, can inferences about population be 
made from these results (based on a sample)? We 
performed necessary calculations for all three log-
rank test variants. Calculations for first ten obser-
vations are shown in Table 2. Step by step proce-
dure for each approach is shown in the supple-
mentary file. After obtaining corresponding P val-
ues, we encounter a controversial situation. When 
Figure 1. Survival curves of myelofibrosis patients with grade < 
3 (blue line marked as 1) and grade 3 (dashed red line marked 
as 2) bone marrow fibrosis and P values obtained with three 
different long-rank tests.  
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P values are reported to three decimal places, the 
Cox-Mantel test suggests that the result is signifi-
cant (P = 0.047), the Peto log-rank test suggest 
that the result is insignificant (P = 0.052), and the 
simple χ2 test suggests that the result is of border-
line statistical significance (P = 0.050). None of the 
methods used is currently considered the gold 
standard, and all three P values can be reported as 
results of the log-rank test. According to our inter-
pretation, our result seems to be truly of border-
line statistical significance as suggested by inho-
mogeneity of obtained P values. Significant asso-
ciation of higher grade of bone marrow fibrosis 
with inferior overall survival was previously report-
ed in multiple cohorts of myelofibrosis patients 
(10-12), although this finding was not universal 
(13). Therefore, we conclude that our data are in 
line with most of previously published results and 
are in support of adverse prognostic significance 
of highly advanced bone marrow fibrosis in these 
patients. However, we cannot consider our result 
alone to represent high level of evidence due to 
borderline statistical significance and retrospec-
tive study design.
Are P values that important?
A recent statement by the American Statistical As-
sociation discussed that no single index should 
substitute for scientific reasoning, and proper in-
ference requires full reporting and transparency; 
e.g. patient selection, contextual factors, number 
of hypotheses explored, measures of effect size, 
etc. (14). Although there are many valid arguments 
against a blind use of specific threshold P values to 
determine statistical significance (and we agree 
they should not be used in that way), P values re-
main an important landmark in scientific decision-
making. Medical literature is overladen with bor-
derline significant results regarding survival bene-
fit of a new drug or a new procedure. Our example 
adds a new dimension to an issue of their appro-
priate interpretation. The statement “the log-rank 
test was used” is not unequivocal as it seems at 
first and this should be of a particular concern in a 
drug regulatory context. Things get especially sus-
picious if different statistical programs are used for 
survival analyses and data analysis in general. 
N Time (months) Status Group I O R RGr1 RGr2 EGr1 EGr2 VMantel
* O/R Λ† W‡ W2
1 0.10 0 1 1 0 67 41 26 0.00 0.00 0.00
2 0.57 1 1 2 1 66 40 26 0.61 0.39 0.24 0.02 0.02 0.98 0.97
3 0.60 1 2 3 1 65 39 26 0.60 0.40 0.24 0.02 0.03 0.97 0.94
4 1.17 1 1 4 1 64 39 25 0.61 0.39 0.24 0.02 0.05 0.95 0.91
5 1.47 1 1 5 1 63 38 25 0.60 0.40 0.24 0.02 0.06 0.94 0.88
6 1.57 1 2 6 1 62 37 25 0.60 0.40 0.24 0.02 0.08 0.92 0.85
7 1.70 1 2 7 1 61 37 24 0.61 0.39 0.24 0.02 0.09 0.91 0.82
8 2.17 0 1 7 1 61 37 24 0.09 0.09 0.01
9 2.23 0 2 7 1 61 37 24 0.09 0.09 0.01
10 4.90 1 2 8 1 58 36 22 0.62 0.38 0.24 0.02 0.11 0.89 0.79
The first ten observations are shown. For specific calculations please see Table 1 and the supplementary file. N – number of 
observation. Time - duration of follow-up, recorded in months in our example. Status - censoring variable, 1 for death and 0 for 
alive or lost to follow-up. Group - 1 for grade < 3 myelofibrosis and 2 for grade 3 myelofibrosis patients. I – number of interval. 
O – observed number of deaths per interval. R – overall number at risk per interval. RGr1 and RGr2 – overall number at risk in a 
specific group per interval. EGr1 and EGr2 – expected number of deaths in a specific group per interval. * Variance of the log-rank test 
calculated by Mantel method. †Λ – the Nelson-Aalen estimator. ‡W – score for the Peto log-rank test.
Table 2. Parameters needed for log rank test calculations obtained in an example data set of myelofibrosis patients 
Biochemia Medica 2017;27(1):14–8  http://doi.org/10.11613/BM.2017.002 
18
Lucijanic M. et al. Survival analysis, more than meets the eye
which all three log-rank test variants should be 
tested, in order to properly evaluate drug efficacy. 
In our opinion, firm result should be significant ir-
respective of the method used. If the result of a 
randomized clinical trial is of borderline statistical 
significance (not consistent among three variants 
of the log-rank test) then it should not be taken as 
the clear evidence of a drug/procedure benefit. 
Regulatory and clinical reasoning should be based 
on the least significant result as the relevant one. 
Definite conclusion would require replicating re-
sults in new independent samples.
Acknowledgements 
Data used for presentation are part of PhD thesis 
of the first author. Authors would like to thank 
Mladen Petrovecki, Rajko Kusec, Ljiljana Miletic 
and Ivo Veletic for support. 
Potential conflict of interest
None declared.
As we previously stated, it would be unethical to 
“fish for significant P value” and to report only one 
most significant result. We would like to point out 
that this danger will exist in borderline significant 
situations until scientific and professional authori-
ties establish the consensus about the log-rank 
test method of choice. Until then, there is proba-
bly no need to insist on the least significant result 
in analysis of retrospective data sets and research-
ers should be adhering to their standard practice/
statistical program of choice. This is because retro-
spective studies are biased by numerous factors. 
Their results do not provide high strength of evi-
dence and usually do not have direct effects on 
clinical practice. However, in a drug regulatory 
context, one must insist on the clear evidence of 
improved survival because randomized clinical tri-
als are taken as a very high level of evidence that 
bears clinical-practice-related and financial impli-
cations. This would perhaps be the situation in 
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